Wuxi Biortus Biosciences Raises US$15M in Series A Financing

Wuxi Biortus Biosciences Co. Ltd., a Wuxi, China-based leader in structural biology service for drug discovery, closed a US$15m Series A financing.

The round was led by Bayland Capital.

The company intends to use the funds to establish a global cryo-EM innovation center.

Biortus is a full-scale contract research organization (CRO) for lead generation in drug discovery, offering services in critical aspects including target protein, in vitro assay, and structural biology. Biortus’s core capabilities include target protein production, biochemical / biophysical / cellular assay development, compound screening and characterization, X-ray crystallography, cryo-EM for protein structure determination (SPA), and MicroED for small molecule crystal form and structure characterization.

The research hub is under construction at Wuxi International Life Science Innovation Campus (I·Campus) in collaboration with Wuxi Municipal Government, Wuxi New District and global biopharmaceutical company AstraZeneca. Phase one construction of the hub will be completed in January of 2021 with first 3 sets of newly purchased cryo-EM instruments including a fully loaded Titan Krios 300kV electron microscope. In the next 3 years, Biortus Cryo-EM will add at least 5 units of high-end electron microscopes to further expand its capacity.



Join the discussion